Antimicrobial susceptibility and heteroresistance in Chinese Clostridium difficile strains

Anaerobe

Volumn 16, Issue 6, 2010, Pages 633-635

  Huang, Haihui ^a,b   Weintraub, Andrej ^b   Fang, Hong ^b   Wu, Shi ^a   Zhang, Yingyuan ^a   Nord, Carl Erik ^b  

^a FUDAN UNIVERSITY   (China)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antimicrobial susceptibility; Clostridium difficile; Resistance mechanisms

Indexed keywords

CIPROFLOXACIN; CLINDAMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ERYTHROMYCIN; FUSIDIC ACID; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; RIFAMPICIN; RIFAXIMIN; RNA POLYMERASE BETA SUBUNIT; TETRACYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; CHINA; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; EMBRYO; GENE MUTATION; HUMAN; HUMAN CELL; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RIBOTYPING;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TYPING TECHNIQUES; CHINA; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; RIBOTYPING;

CLOSTRIDIUM DIFFICILE;

EID: 78650578077     PISSN: 10759964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anaerobe.2010.09.002     Document Type: Article

References (20)

1. Kelly C.P., LaMont J.T. Clostridium difficile-more difficult than ever. N Engl J Med 2008, 359:1932-1940.
2. Coia J.E. What is the role of antimicrobial resistance in the new epidemic of Clostridium difficile?. Int J Antimicrob Agents 2009, 33(Suppl. 1):S9-S12.
3. Peláez T., Alcalá L., Alonso R., Rodríguez-Créixems M., García-Lechuz J.M., Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002, 46:1647-1650.
4. Zheng L., Keller S.F., Lyerly D.M., Carman R.J., Genheimer C.W., Gleaves C.A., et al. Multicenter evaluation of a new screening test that detects Clostridium difficile in fecal specimens. J Clin Microbiol 2004, 42:3837-3840.
5. Kato H., Kato N., Watanabe K., Iwai N., Nakamura H., Yamamoto T., et al. Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 1998, 36:2178-2182.
6. Huang H., Weintraub A., Fang H., Nord C.E. Comparison of a commercial multiplex real-time PCR and the cell cytotoxicity neutralization assay for the diagnosis of Clostridium difficile infections. J Clin Microbiol 2009, 47:3729-3731.
7. Stubbs S.L., Brazier J.S., O'Neill G.L., Duerden B.I. PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 1999, 37:461-463.
8. Clinical and Laboratory Standards Institute Methods for antimicrobial susceptibility testing of anaerobic bacteria 2007, Approved standard M11-A7, CLSI, Wayne, PA. 7th ed.
9. Huang H., Wu S., Wang M., Zhang Y., Fang H., Palmgren A.C., et al. Clostridium difficile infections in a Shanghai hospital: antimicrobial resistance, toxin profiles and ribotypes. Int J Antimicrob Agents 2009, 33:339-342.
10. Peláez T., Cercenado E., Alcalá L., Marín M., Martín-López A., Martínez-Alarcón J. Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 2008, 46:3028-3032.
11. Spigaglia P., Barbanti F., Mastrantonio P. Detection of a genetic linkage between genes coding for resistance to tetracycline and erythromycin in Clostridium difficile. Microb Drug Resist 2007, 13:90-95.
12. Schmidt C., Löffler B., Ackermann G. Antimicrobial phenotypes and molecular basis in clinical strains of Clostridium difficile. Diagn Microbiol Infect Dis 2007, 59:1-5.
13. Drudy D., Quinn T., O'Mahony R., Kyne L., O'Gaora P., Fanning S. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 2006, 58:1264-1267.
14. Norén T., Akerlund T., Wullt M., Burman L.G., Unemo M. Mutations in fusA associated with posttherapy fusidic acid resistance in Clostridium difficile. Antimicrob Agents Chemother 2007, 51:1840-1843.
15. Curry S.R., Marsh J.W., Shutt K.A., Muto C.A., O'Leary M.M., Saul M.I., et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009, 48:425-429.
16. Goorhuis A., Legaria M.C., van den Berg R.J., Harmanus C., Klaassen C.H., Brazier J.S., et al. Application of multiple-locus variable-number tandem-repeat analysis to determine clonal spread of toxin A-negative Clostridium difficile in a general hospital in Buenos Aires, Argentina. Clin Microbiol Infect 2009, 15:1080-1086.
17. Cheng V.C., Yam W.C., Chan J.F., To K.K., Ho P.L., Yuen K.Y. Clostridium difficile ribotype 027 arrives in Hong Kong. Int J Antimicrob Agents 2009, 34:492-493.
18. Goorhuis A., Bakker D., Corver J., Debast S.B., Harmanus C., Notermans D.W., et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008, 47:1162-1170.
19. Spigaglia P., Barbanti F., Mastrantonio P. Tetracycline resistance gene tet(W) in the pathogenic bacterium Clostridium difficile. Antimicrob Agents Chemother 2008, 52:770-773.
20. Spigaglia P., Barbanti F., Louie T., Barbut F., Mastrantonio P. Molecular analysis of the gyrA and gyrB quinolone resistance-determining regions of fluoroquinolone-resistant Clostridium difficile mutants selected in vitro. Antimicrob Agents Chemother 2009, 53:2463-2468.